105 related articles for article (PubMed ID: 16928830)
1. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.
Qian X; LaRochelle WJ; Ara G; Wu F; Petersen KD; Thougaard A; Sehested M; Lichenstein HS; Jeffers M
Mol Cancer Ther; 2006 Aug; 5(8):2086-95. PubMed ID: 16928830
[TBL] [Abstract][Full Text] [Related]
2. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer.
Dizon DS; Damstrup L; Finkler NJ; Lassen U; Celano P; Glasspool R; Crowley E; Lichenstein HS; Knoblach P; Penson RT
Int J Gynecol Cancer; 2012 Jul; 22(6):979-86. PubMed ID: 22694911
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.
Buckley MT; Yoon J; Yee H; Chiriboga L; Liebes L; Ara G; Qian X; Bajorin DF; Sun TT; Wu XR; Osman I
J Transl Med; 2007 Oct; 5():49. PubMed ID: 17935615
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).
Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Buhl-Jensen P; Molife R; Brown R; de Bono JS; Evans TR
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1273-9. PubMed ID: 20706839
[TBL] [Abstract][Full Text] [Related]
5. Belinostat for the treatment of peripheral T-cell lymphomas.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834
[TBL] [Abstract][Full Text] [Related]
6. Belinostat: clinical applications in solid tumors and lymphoma.
Molife LR; de Bono JS
Expert Opin Investig Drugs; 2011 Dec; 20(12):1723-32. PubMed ID: 22046971
[TBL] [Abstract][Full Text] [Related]
7. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
Gimsing P
Expert Opin Investig Drugs; 2009 Apr; 18(4):501-8. PubMed ID: 19335278
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
Tumber A; Collins LS; Petersen KD; Thougaard A; Christiansen SJ; Dejligbjerg M; Jensen PB; Sehested M; Ritchie JW
Cancer Chemother Pharmacol; 2007 Jul; 60(2):275-83. PubMed ID: 17124594
[TBL] [Abstract][Full Text] [Related]
9. Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat.
Beck HC; Petersen J; Nielsen SJ; Morsczeck C; Jensen PB; Sehested M; Grauslund M
Electrophoresis; 2010 Aug; 31(16):2714-21. PubMed ID: 20717991
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Rasmussen A; Ooi CE; Buhl-Jensen P; Brown R; Evans TR; DeBono JS
Clin Cancer Res; 2008 Feb; 14(3):804-10. PubMed ID: 18245542
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.
Kim MJ; Lee JS; Park SE; Yi HJ; Jeong IG; Kang JS; Yun J; Lee JY; Ro S; Lee JS; Choi EK; Hwang JJ; Kim CS
J Urol; 2015 May; 193(5):1660-8. PubMed ID: 25433307
[TBL] [Abstract][Full Text] [Related]
12. Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Bodiford A; Bodge M; Talbott MS; Reddy NM
Onco Targets Ther; 2014; 7():1971-7. PubMed ID: 25368524
[TBL] [Abstract][Full Text] [Related]
13. Belinostat: first global approval.
Poole RM
Drugs; 2014 Sep; 74(13):1543-54. PubMed ID: 25134672
[TBL] [Abstract][Full Text] [Related]
14. Belinostat approved for use in treating rare lymphoma.
Thompson CA
Am J Health Syst Pharm; 2014 Aug; 71(16):1328. PubMed ID: 25074945
[No Abstract] [Full Text] [Related]
15. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain.
Wang C; Eessalu TE; Barth VN; Mitch CH; Wagner FF; Hong Y; Neelamegam R; Schroeder FA; Holson EB; Haggarty SJ; Hooker JM
Am J Nucl Med Mol Imaging; 2013; 4(1):29-38. PubMed ID: 24380043
[TBL] [Abstract][Full Text] [Related]
17. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
Lin SF; Lin JD; Chou TC; Huang YY; Wong RJ
PLoS One; 2013; 8(10):e77684. PubMed ID: 24155971
[TBL] [Abstract][Full Text] [Related]
18. A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity.
Rajak H; Singh A; Raghuwanshi K; Kumar R; Dewangan PK; Veerasamy R; Sharma PC; Dixit A; Mishra P
Curr Med Chem; 2014; 21(23):2642-64. PubMed ID: 23895688
[TBL] [Abstract][Full Text] [Related]
19. LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.
Kiesel BF; Parise RA; Tjørnelund J; Christensen MK; Loza E; Tawbi H; Chu E; Kummar S; Beumer JH
J Pharm Biomed Anal; 2013; 81-82():89-98. PubMed ID: 23644904
[TBL] [Abstract][Full Text] [Related]
20. A novel platinum complex of the histone deacetylase inhibitor belinostat: rational design, development and in vitro cytotoxicity.
Parker JP; Nimir H; Griffith DM; Duff B; Chubb AJ; Brennan MP; Morgan MP; Egan DA; Marmion CJ
J Inorg Biochem; 2013 Jul; 124():70-7. PubMed ID: 23603796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
